# Nuclide record f-alpha-therapy (section). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/fronts/f-alpha-therapy/>
  a schema:DefinedTerm ;
  nuclide:kind "section" ;
  schema:identifier "f-alpha-therapy" ;
  schema:name "Targeted alpha therapy"@en ;
  schema:description "Alpha therapy uses a heavier type of radioactive particle that travels only a few cell widths but hits much harder, aimed at cancer cells that have stopped responding to the gentler beta-particle treatments."@en ;
  schema:url <https://nuclide.cc/fronts/f-alpha-therapy/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www-pub.iaea.org/MTCD/publications/PDF/TE-2057web.pdf>, <https://www.nejm.org/doi/10.1056/NEJMoa1213755>, <https://www.ans.org/news/2026-01-14/article-7675/iaeas-global-radium226-management-initiative-continues-to-progress/>, <https://www.mdpi.com/2072-6694/17/18/3055> ;
  nuclide:related <https://nuclide.cc/fronts/f-radioligand-therapy/>, <https://nuclide.cc/fronts/f-isotope-supply/>, <https://nuclide.cc/fronts/f-bone-targeted/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/ra-223/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/metastatic-ppgl/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/actinium-225-supply/>, <https://nuclide.cc/technologies/astatine-211-alpha-therapy/>, <https://nuclide.cc/technologies/alpha-nanogenerators/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/drugs/radium-223/> ;
  nuclide:companies <https://nuclide.cc/companies/fusion-pharma/>, <https://nuclide.cc/companies/rayzebio/>, <https://nuclide.cc/companies/perspective-therapeutics/>, <https://nuclide.cc/companies/orano-med/>, <https://nuclide.cc/companies/actinium-pharmaceuticals/>, <https://nuclide.cc/companies/artbio/>, <https://nuclide.cc/companies/convergent-therapeutics/> ;
  nuclide:terms <https://nuclide.cc/terms/alpha-vs-beta/> ;
  nuclide:trials <https://nuclide.cc/trials/alsympca/>, <https://nuclide.cc/trials/alphabreak/>, <https://nuclide.cc/trials/nct05219500/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-alsympca-radium-223-nejm-2013/> .